Picture of Tyra Biosciences logo

TYRA Tyra Biosciences Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMid CapNeutral

Annual cashflow statement for Tyra Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
2023
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:PROSPECTUS10-Q10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-4.07-9.34-26.3-55.3-69.1
Depreciation
Non-Cash Items0.9340.4542.8910.612.3
Unusual Items
Other Non-Cash Items
Changes in Working Capital0.5051.07-0.481-5.856.36
Change in Prepaid Expenses
Change in Accounts Payable
Change in Accrued Expenses
Other Operating Cash Flow
Cash from Operating Activities-2.62-7.76-23.7-50.3-50.1
Capital Expenditures-0.02-0.312-0.661-0.559-0.77
Purchase of Fixed Assets
Other Investing Cash Flow Items0.0160-144
Sale of Fixed Assets
Purchase of Investments
Cash from Investing Activities-0.02-0.312-0.645-0.559-145
Financing Cash Flow Items0.165-0.025
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities0.15723.43110.6321.54
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash-2.4815.4287-50.2-193